PE20211334A1 - Formula antibiotica inyectable de liberacion sostenida - Google Patents

Formula antibiotica inyectable de liberacion sostenida

Info

Publication number
PE20211334A1
PE20211334A1 PE2021000294A PE2021000294A PE20211334A1 PE 20211334 A1 PE20211334 A1 PE 20211334A1 PE 2021000294 A PE2021000294 A PE 2021000294A PE 2021000294 A PE2021000294 A PE 2021000294A PE 20211334 A1 PE20211334 A1 PE 20211334A1
Authority
PE
Peru
Prior art keywords
composition
sustained release
release injectable
injectable antibiotic
active agent
Prior art date
Application number
PE2021000294A
Other languages
English (en)
Inventor
Michael Friedman
David Kirmayer
Zakhar Nudelman
Amnon Hoffman
Eran Lavy
Ayala Bar-Hai
Irith Gati
Original Assignee
Yissum Research Development Company Of The Hebrew Univ Of Jerusalen Ltd
Agrinnovation Yissum G P Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew Univ Of Jerusalen Ltd, Agrinnovation Yissum G P Ltd filed Critical Yissum Research Development Company Of The Hebrew Univ Of Jerusalen Ltd
Publication of PE20211334A1 publication Critical patent/PE20211334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion define una composicion farmaceutica que comprende un agente biologicamente activo, poloxamero, un vehiculo acuoso y un codisolvente organico, en donde dicha composicion es una composicion inyectable a temperatura ambiente, con la condicion de que en donde dicha concentracion del agente activo es inferior al 35 % en peso de la composicion. Adicionalmente comprende un material a base de celulosa que es al menos parcialmente soluble en disolventes organicos. Las composiciones de antibioticos inyectables son de su uso veterinario.
PE2021000294A 2018-09-06 2019-09-05 Formula antibiotica inyectable de liberacion sostenida PE20211334A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862727574P 2018-09-06 2018-09-06
PCT/IL2019/050998 WO2020049570A1 (en) 2018-09-06 2019-09-05 Sustained-release injectable antibiotical formulation

Publications (1)

Publication Number Publication Date
PE20211334A1 true PE20211334A1 (es) 2021-07-22

Family

ID=68072920

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000294A PE20211334A1 (es) 2018-09-06 2019-09-05 Formula antibiotica inyectable de liberacion sostenida

Country Status (14)

Country Link
US (1) US20210315803A1 (es)
EP (1) EP3846781A1 (es)
JP (1) JP2021536485A (es)
KR (1) KR20210099553A (es)
CN (1) CN113412109A (es)
BR (1) BR112021004192A2 (es)
CA (1) CA3111385A1 (es)
CL (1) CL2021000536A1 (es)
CO (1) CO2021004131A2 (es)
EA (1) EA202190672A1 (es)
MX (1) MX2021002492A (es)
PE (1) PE20211334A1 (es)
PH (1) PH12021550477A1 (es)
WO (1) WO2020049570A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306211B (zh) * 2021-12-29 2023-12-22 中国药科大学 一种甘草酸超分子自组装温敏互穿网络凝胶及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US6201065B1 (en) 1995-07-28 2001-03-13 Focal, Inc. Multiblock biodegradable hydrogels for drug delivery and tissue treatment
EP1109563A4 (en) 1998-08-04 2009-07-22 Madash Llp HEAT-SENSITIVE HYDROGELS WITH MODIFIED TERMINATION
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
NZ555774A (en) * 2004-12-21 2010-09-30 Intervet Int Bv Injectable veterinary composition comprising florfenicol, a pyrrolidone solvent and a cosolvent selected from diethyleneglycol monoethyl ether and / or tetrahydrofurfuryl alcohol polyethylene glycol ether
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US8614315B2 (en) * 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
BR112013001594A2 (pt) * 2010-07-22 2016-05-17 Reven Pharmaceuticals Inc métodos de tratamento ou melhoria de doenças e para melhorar o desempenho compreendendo o uso de uma solução dipolo magnético estabilizada
BR112013024863A2 (pt) 2011-03-28 2016-12-20 Yissum Res Dev Co formulação injetável de liberação sustentada
CN103202802A (zh) 2013-04-22 2013-07-17 南京农业大学 氟苯尼考注射用原位凝胶及其制备方法
CN107708667A (zh) * 2015-06-16 2018-02-16 太阳医药高级研发有限公司 长效利拉鲁肽组合物

Also Published As

Publication number Publication date
EP3846781A1 (en) 2021-07-14
CN113412109A (zh) 2021-09-17
MX2021002492A (es) 2021-09-08
JP2021536485A (ja) 2021-12-27
WO2020049570A1 (en) 2020-03-12
EA202190672A1 (ru) 2021-07-01
CL2021000536A1 (es) 2021-08-20
US20210315803A1 (en) 2021-10-14
CA3111385A1 (en) 2020-03-12
CO2021004131A2 (es) 2021-07-30
BR112021004192A2 (pt) 2021-05-25
PH12021550477A1 (en) 2021-11-22
KR20210099553A (ko) 2021-08-12

Similar Documents

Publication Publication Date Title
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
CL2020000739A1 (es) Agente prolongado de control de ectoparasito para animales.
ES2524771T3 (es) Composiciones farmacéuticas que comprenden levetiracetam y procedimientos para su preparación
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CL2017000287A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CO2019014484A2 (es) Nuevos derivados de azaquinolina
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
AR089074A1 (es) Preparacion de liberacion prolongada que comprende composicion en gel que se orienta a las plagas tipo insectos
ECSP20008441A (es) Dihidrooxadiazinonas
CL2020002891A1 (es) Nuevos derivados de quinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR071533A1 (es) Microemulsion mejorada con un amplio rango de aplicacion
CL2018003178A1 (es) Composición farmacéutica
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY31780A (es) Fenoxibenzamidas sustituidas
CR20160462A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
PE20211334A1 (es) Formula antibiotica inyectable de liberacion sostenida
UY38816A (es) Nuevos derivados de isoquinolina
AR052882A1 (es) Composicion antihelmintica